Mosaic ImmunoEngineering Inc. signs license-option to advance novel immunotherapy to treat cancer and infectious

Mosaic ImmunoEngineering Inc., a private biotechnology company based in Novato, California, has signed a two-year option agreement with Case Western Reserve University and Dartmouth College, granting the company the exclusive right to license technology for a novel platform technology using virus-like nanoparticles (“VLP”) to treat and prevent cancer and infectious diseases in humans and for veterinary use.

Click here to read the complete story.

Story excerpt provided by Mirage News.

Originally published August 31, 2020.